Dennis Karp
Executive Chairman |
Manuka Resources
201-207 Kent Street,
NSW 2000 Sydney (AU)
admin@manukaresources.com.au
+61 2 72 532 020
Manuka Resources Interview: Where cash flows and blue sky potential come together
September 19th, 2022
ASX listed Manuka Resources combines the stability of a producer and the opportunity of a growth company. Its two projects producing gold and silver generate cash flows on the one hand yet have enormous potential for further development on the other - no wonder the gold resource in particular continues to grow despite increasing production volumes. Recently, the well-connected management team achieved another coup acquiring a very large iron sands and vanadium project in New Zealand. The South Taranaki Bight project (STB project) hosts a VTM iron sands deposit (vanadium, titanomagnetite iron sands) with outstanding PFS economics, unique environmental credentials and is scheduled to be in production within a few years. Even today, vanadium is to infrastructure projects and utility energy storage, what lithium is to electromobility, ie: absolutely critical. We talked to Dennis Karp, Executive Chairman of Manuka Resources, about the prospects and facts surrounding Manuka’s project portfolio.
Brodie Sutherland
CEO |
Tocvan Ventures
820 – 1130 West Pender St,
V6E 4A4 Vancouver (CAN)
Bsutherland@tocvan.ca
+ 1 403 829 9877
Interview with Tocvan Ventures: "High gold content and low costs have convinced professional investors despite the crisis”.
July 12th, 2022
Tocvan Ventures has come up with several impressive developments in recent weeks: In addition to obtaining financing despite a challenging market environment, the gold prospector identified new zones of mineralization on both its projects in Mexico. The grades have caused a stir within the mining scene. In an interview, CEO and geologist Brodie Sutherland explains why Tocvan Ventures has two hot irons in the fire, what role Mexico plays as a location, and how the team intends to continue creating value in the future.
Tim Daniels
CEO |
Erin Ventures
645 Fort Street, Suite 203,
BC V8W 1G2 Victoria (CAN)
info@erinventures.com
Interview Erin Ventures: "Many megatrends involve boron, but the market is still in its infancy"
June 29th, 2022
Batteries for electric cars, fuel cells, wind turbines, solar panels, LCD screens and fertilizers: Boron is versatile and hardly replaceable. So far, two players share 75% of the market and are making a killing. Erin Ventures has a boron project in Serbia and recently published convincing key economic data. The only other major players in Boron are the government owned Eti Maden in Turkey, and Rio Tinto in California. Thanks to the figures, Erin even managed to attract a joint venture partner, at the project level, in these challenging times to take on financing risks and minimize future dilution for shareholders. CEO Tim Daniels talks about the market for boron and the opportunities for Erin Ventures, which is only in the single digits.
Joe Bleackley
CEO |
Pathfinder Ventures Inc.
9451 Glover Road, PO,
V1M 2R9 Box 610 Fort Langley, BC (CAN)
ir@pathfinderventures.ca
Interview with campsite operator Pathfinder Ventures: "We create unforgettable family experiences and set new standards."
June 27th, 2022
Going out into nature in your own motorhome and switching off for a while has long since become a ritual for many families. Pathfinder Ventures currently operates three RV Resorts & campgrounds in British Columbia and has set itself the task of consolidating the predominantly family owned campground market, and also building new locations at the same time. In an interview, CEO, camping enthusiast Joe Bleackley explains how the Company plans to attract customers and investors alike and where Pathfinder Ventures plays to its strengths.
Ryan McDermott
CEO |
Phoenix Copper
OMC Chambers, Wickhams Cay 1, ROAD TOWN,
VG1110 Virgin Islands (British) (GB)
hello@pgmining.com
Interview Phoenix Copper: Copper with certain advantages
April 29th, 2022
Phoenix Copper could go into production as early as 2023 and surprise the market with its production costs and other general conditions. In an interview, CEO Ryan McDermott explains why the Company doesn't believe in making a lot of promises, why the planned Empire Open Pit project doesn't anticipate any environmental impacts, and what other potential lies dormant in the Company.
Bill Radvak
CEO |
NervGen Pharma
2955 Virtual Way, Suite 480,
V5M 4X6 Vancouver, BC (CAN)
info@nervgen.com
+1 604.537.2094
Interview NervGen Pharma: "We have a drug with the potential to treat Alzheimer's, MS, spinal cord injury and stroke".
April 14th, 2022
Multiple sclerosis, Alzheimer's disease or even strokes have something in common with spinal cord injury: they damage the nervous system. This makes them all incredibly difficult to treat. But a therapeutic breakthrough finally seems possible. In the 1990s, Dr. Jerry Silver discovered the root cause for why debilitating damage to the central nervous system cannot be repaired. What was a revolutionary discovery at the time is now accepted science. The NervGen team, which has exclusively licensed the technology that came from Dr. Silver’s lab, is now at an exciting time in the development of a potentially paradigm changing milestone, based on his 30 years of important work. The breakthrough could come as early as next year. We talk about NervGen's approach and plans for a Nasdaq listing with NervGen Executive Chairman Bill Radvak.
Dylan Ong
General Manager and Executive Director |
Hong Lai Huat
10 Bukit Batok Crescent, #13-05, The Spire,
S658079 Singapore (SG)
general@hlh.com.sg
+65 6861 0330
Interview Hong Lai Huat: Real estate in Cambodia promises high margins
April 6th, 2022
Cambodia offers breathtaking beaches, the world wonder of the Angkor Wat temples and an emerging economy: the rating agency Fitch expects growth of 4.7% in 2022. In this interview, Dylan Ong, General Manager and Executive Director of Hong Lai Huat, explains the opportunities offered by Cambodia's real estate market, why the Group has an edge over other investors, and which joint venture could generate big fantasy as early as 2022.
David Elsley
CEO |
Cardiol Therapeutics
602-2265 Upper Middle Road East,
L6H 0G5 Oakville (CAN)
info@cardiolrx.com
+1 (289) 910-0850
Interview Cardiol Therapeutics: 'We have two potential blockbusters in our portfolio'
March 10th, 2022
In this interview, Cardiol Therapeutics’ President and CEO David Elsley explains the unique selling points of the Company’s lead product, CardiolRx™, an oral cannabidiol formulation pharmaceutically manufactured under cGMP. He explains why the upcoming clinical trials could result in exclusive multi-year distribution agreements, why the financing last November was a good decision, and how major funds from the U.S. currently stand by Cardiol Therapeutics.
Terry Lynch
CEO |
Power Nickel
82 Richmond St East Suite 202,
M5C 1P1 Toronto (CAN)
info@powernickel.com
+1 416 900-5445
Power Nickel Interview: 'The coming quarters change everything.'
March 8th, 2022
A promising nickel project in Quebec, several gold properties in Canada and Chile, and a license agreement with Teck Resources that could yet provide surprises - Power Nickel's list of activities is long. But the Company is consolidating. As early as the second quarter, historical data is expected to be converted into an updated resource estimate for the flagship NISK project. Shareholders also stand to receive bonus shares later this year. Here is what Terry Lynch, CEO of Power Nickel, has in mind for 2022 and what the Company needs to do to be valued at CAD 800 million instead of CAD 15 million.
Dr. Moutih Rafei
Director and VP of research and development |
Defence Therapeutics
1680 – 200 Burrard Street,
V6C 3L6 Vancouver (CAN)
info@defencetherapeutics.com
+1 (514) 947 2272
Defence Therapeutics Interview: 'Accum™ is the most sought-after multi-tool in the pharmaceutical industry.'
February 23rd, 2022
The case of the German biotech CureVac has shown that costly projects often fail because of the finer details. Canadian biotech Defence Therapeutics has developed a drug enhancer with its patented Accum™ technology, which works with many technologies and, even on its own, has a highly toxic effect on cancer cells. Dr. Moutih Rafei, director and VP of research and development at Defence Therapeutics, explains in an interview how Defence Therapeutics is working toward upcoming Phase I trials around vaccines for breast and skin cancer, how else the versatile technology can be used, and to which pharma giants it has specific scientific tie-ins.
Uwe Ahrens
Director |
Altech Advanced Materials AG
Ziegelhäuser Landstraße 3,
69120 Heidelberg (DE)
info@altechadvancedmaterials.com
Interview Altech Advanced Materials: "We make batteries in e-cars more powerful and more durable".
January 27th, 2022
Uwe Ahrens, director of Altech Advanced Materials, is convinced that e-cars will soon be cheaper than combustion engines. Ahrens and his team are pushing ahead with innovations and are not afraid of a price war in the battery industry. The reason: with its technology, the Company sees the potential to make batteries for e-cars significantly more powerful. Find out how this works and what other aces Altech Advanced Materials has up its sleeve in an interview with the experienced industry manager.
Gary Cope
President and CEO |
Barsele Minerals
Suite 1130 - 1055 W. Hastings Street,
V6E 2E9 Vancouver (CAN)
info@barseleminerals.com
+1(604) 687-8566
Interview Barsele Minerals: 'We will cut the Gordian Knot'
December 15th, 2021
Barsele Minerals operates its promising Swedish Barsele project in a joint venture with commodity giant Agnico Eagle. The project scores with high grades and the potential for up to 4 million ounces of gold. Sweden is attractive due to low energy prices and secure framework conditions. But Agnico Eagle sees its future more in North America. The necessary exploration budget to make the breakthrough at Barsele has so far failed to materialize. Now new options are opening up. In an interview, Barsele CEO Gary Cope explains the background and draws parallels to a billion-dollar company.